Cerus Corporation is thrilled to publicize the latest 16th Annual Hemovigilance report published by the French National Agency for Medicines and Health Products which supervises the safety of drugs and various other health products. In the report, the safety and efficiency of INTERCEPT platelets during the initial complete year of routine administration is outlined.
The president and CEO of Cerus, William ‘Obi’ Greenman stated how the latest hemovigilance data published by the French National Agency for Medicines and Health Products emphasizes the safety benefits acquired through using the INTERCEPT Blood Systems for platelets. He stated that they were honored to be able to state how each patient in France who received the platelet transfusion is reaping the benefits of their pathogen-reduction technology.
The chief medical officer at Cerus, Dr. Richard Benjamin stated how the French Hemovigilance system is the sturdiest surveillance system around the globe when it comes to transfusion safety, and that it is heartening to see that the INTERCEPT system delivered the predicted safeguard to the French platelet supply at its initial use in full routine at 100%. He stated how they believe that this huge data set documenting the French experience will add to the confidence of blood centers and hospitals based in the United Stated as they look forward to the rise in use of INTERCEPT to live up to the FDA’s Guidance Document regarding platelet bacterial safety.
In 1993, the French national hemovigilance system was developed by law to identify and lessen the risk of negative cased linked to blood transfusions. The national system was formed by the joining of forces of the Regional Hemovigilance and Blood Safety Coordinators, ANSM, the Armed Forces Blood Transfusion Center, the French Public Health Agency, and the French National Blood Service.